CA2168647A1 - Monogenous preparations of cytotoxic conjugates - Google Patents

Monogenous preparations of cytotoxic conjugates

Info

Publication number
CA2168647A1
CA2168647A1 CA002168647A CA2168647A CA2168647A1 CA 2168647 A1 CA2168647 A1 CA 2168647A1 CA 002168647 A CA002168647 A CA 002168647A CA 2168647 A CA2168647 A CA 2168647A CA 2168647 A1 CA2168647 A1 CA 2168647A1
Authority
CA
Canada
Prior art keywords
fgf
modified
saporin
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002168647A
Other languages
English (en)
French (fr)
Inventor
Barbara A. Sosnowski
Douglas A. Lappi
Andrew J. Baird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whittier Institute for Diabetes and Endocrinology
Selective Genetics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2168647A1 publication Critical patent/CA2168647A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
CA002168647A 1993-08-02 1994-07-27 Monogenous preparations of cytotoxic conjugates Abandoned CA2168647A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9992493A 1993-08-02 1993-08-02
US08/099,924 1993-08-02
US14582993A 1993-10-29 1993-10-29
US08/145,829 1993-10-29

Publications (1)

Publication Number Publication Date
CA2168647A1 true CA2168647A1 (en) 1995-02-09

Family

ID=26796629

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002168647A Abandoned CA2168647A1 (en) 1993-08-02 1994-07-27 Monogenous preparations of cytotoxic conjugates

Country Status (5)

Country Link
EP (1) EP0712314A1 (ja)
JP (1) JPH09503751A (ja)
AU (1) AU7475694A (ja)
CA (1) CA2168647A1 (ja)
WO (1) WO1995003831A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008293A1 (en) * 1992-12-23 1996-03-21 Patrick Edison Kane Injection molded water-soluble golf ball
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
EP1188448A3 (en) * 1994-03-15 2002-04-17 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
AU3724495A (en) * 1994-09-13 1996-03-29 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
EP0804479B1 (en) * 1994-10-13 2006-10-11 Amgen Inc., Method of treating diabetes mellitus using kgf
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US5728546A (en) 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
US6403557B1 (en) 1996-11-27 2002-06-11 Human Genome Sciences, Inc. Fibroblast growth factor-13
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
JP3708210B2 (ja) * 1996-04-03 2005-10-19 協和醗酵工業株式会社 抗線維芽細胞増殖因子−８モノクローナル抗体
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
JP4880118B2 (ja) * 1997-11-17 2012-02-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 薬物高充填性の即時放出性または放出を修飾した経口用投与処方およびその製法
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
PL373511A1 (en) * 2001-05-15 2005-09-05 Faulk Pharmaceuticals, Inc. Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
PL238516B1 (pl) * 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu
CN111358937A (zh) * 2020-02-27 2020-07-03 广州领晟医疗科技有限公司 Fgf-2衍生多肽在制备促进软骨修复和/或治疗骨关节炎药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890701607A (ko) * 1987-11-24 1989-12-21 원본미기재 섬유아세포 성장 인자의 유사체
GB8801877D0 (en) * 1988-01-28 1988-02-24 Erba Carlo Spa Nucleotide sequence encoding plant ribosome inactivating protein
EP0552188B1 (en) * 1990-09-19 1998-03-11 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with fgf-cytotoxic conjugates
WO1993025688A1 (en) * 1992-06-16 1993-12-23 Whittier Institute For Diabetes And Endocrinology Recombinant production of saporin-containing proteins

Also Published As

Publication number Publication date
JPH09503751A (ja) 1997-04-15
WO1995003831A1 (en) 1995-02-09
AU7475694A (en) 1995-02-28
EP0712314A1 (en) 1996-05-22

Similar Documents

Publication Publication Date Title
CA2168647A1 (en) Monogenous preparations of cytotoxic conjugates
AU702323B2 (en) Heparin-binding growth factors for gene therapy and anterior eye disorders
US6037329A (en) Compositions containing nucleic acids and ligands for therapeutic treatment
US5576288A (en) Fibroblast growth factor conjugates
EP0382781B1 (en) Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
WO1996006641A1 (en) Conjugates of vascular endothelial growth factor with targeted agents
CA2053275C (en) Fibroblast growth factor conjugates
AU710309B2 (en) Compositions containing nucleic acids and ligands for therapeutic treatment
WO1996008274A2 (en) Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
US20090093400A1 (en) Truncated keratinocyte growth factor (KGF) having increased biological activity
US5916772A (en) Recombinant production of saporin-containing proteins
CA2295189C (en) Type-1 ribosome-inactivating protein
KR102629006B1 (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
EP0923387B1 (en) Heparin-coated medical devices for intravenous use containing heparin-binding growth factor conjugates
WO1997049434A9 (en) Heparinized medical devices containing heparin-binding growth factor conjugates
US20030040496A1 (en) Methods for halting unwanted cell growth, such as using ligand-directed nucleic acid delivery vehicles
EP0341304A1 (en) Improved ricin molecules and ricin toxin conjugates
US20050090445A1 (en) Truncated keratinocyte growth factor (KGF) having increased biological activity

Legal Events

Date Code Title Description
FZDE Dead